IP Library Granted Patent US 7,994,298
Granted Patent B2
US 7,994,298 · App. 11/575,878 · Granted Aug 9, 2011

Chimeric NK receptor and methods for treating cancer

Assignee: Trustees of Dartmouth College
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,994,298
App. No.
11/575,878
Granted
Aug 9, 2011
Kind
B2
Abstract

The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.

Claims (5)

1. A nucleic acid construct for expressing a chimeric receptor comprising:

a first nucleic acid sequence encoding a promoter operably linked to a second nucleic acid sequence encoding a chimeric receptor comprising a C-type lectin-like natural killer cell receptor, fused to a nucleic acid encoding an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif of SEQ ID NO: 1.

2. The nucleic acid construct of claim 1 , wherein the construct is in a vector.

3. The nucleic acid construct of claim 1 further comprising a suicide gene.

4. An isolated T cell comprising the nucleic acid construct of claim 1 or 3 , or the vector of claim 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2007
From: ZHANG, TONG; SENTMAN, CHARLES L.
To: TRUSTEES OF DARTMOUTH COLLEGE
Reel/Frame 019186/0244 →
Continuity (3)
Provisional Application 60681782 · May 17, 2005
Provisional Application 60612836 · Sep 24, 2004
Related Publication 20100029749A1 · Feb 4, 2010